Live from TTLC 2026: Emerging Molecular Targets in Non-Small Cell Lung Cancer (NSCLC)

Catalog

VIKTOR

Podcast | English | 2026 | 42 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms, and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Kelsey Pan, MD, MPH, Assistant Professor of Medicine, Department of Hematology & Oncology Section, Emory University Winship Cancer Institute, Atlanta, GA, USA
Rajat Thawani, MD, Assistant Professor of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, OHSU, Portland, OR, USA